<DOC>
	<DOCNO>NCT01103609</DOCNO>
	<brief_summary>The purpose study determine whether AZD1656 affect Pharmacokinetics Pharmacodynamics Warfarin T2DM patient .</brief_summary>
	<brief_title>Investigate Effect AZD1656 Pharmacokinetics Pharmacodynamics Warfarin Type 2 Diabetes Mellitus ( T2DM ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Clinical diagnosis T2DM treat least 1000 mg metformin single treatment combination one oral antidiabetic least 2 month prior screen . Doses antidiabetic treatment stable least 1 month Fasting plasma glucose ( FPG ) screen range 6.0 15.0 mmol/L ( 108 270 mg/dL ) FPG range 7.5 13.0 mmol/L ( 135 234 mg/dL ) Day 1 Haemoglobin ( Hb ) A1c &gt; 6.5 % screening Use drug anticoagulant effect 3 week prior first warfarin dosing Use amiodarone within 3 month prior screen use potent CYP450 inhibitor Previous treatment warfarin clinical indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Warfarin</keyword>
	<keyword>drug-drug interaction</keyword>
</DOC>